表紙
市場調查報告書

肺炎的診斷:美國

Pneumonia - Diagnosis Report

出版商 Boston Strategic Partners, Inc. 商品編碼 557104
出版日期 內容資訊 英文 55 Pages
訂單完成後即時交付
價格
肺炎的診斷:美國 Pneumonia - Diagnosis Report
出版日期: 2017年07月31日內容資訊: 英文 55 Pages
簡介

本報告提供必須住院治療的肺炎,在美國的診斷趨勢調查,患者的住院途徑與檢查、治療的流程,患者簡介,成為原因的病原體,患者屬性的住院期間與費用,臨床檢驗和各種項目的週轉時間,藥物抗性肺炎相關各種資料、統計等彙整資料。

患者的流程

摘要整理

患者人口統計

  • 年齡
  • 保險類型
  • 性別
  • 地區
  • 死亡率
  • 並存症

診斷檢驗的患者感染區分

  • 成為原因的病原體

住院期間、費用:各患者屬性

  • 住院時的年齡
  • APACHE II評分
  • 初期治療環境

醫院的患者流動

  • 住院網站
  • 臨床檢驗
  • 週轉時間
  • 結果
  • 病因

藥物抗性肺炎

  • 目前趨勢
  • 成本
  • 並存症
  • 住院日數
  • 死亡率

資料庫概要

調查手法

目錄

In 2014, US healthcare spending exceeded $3.0 trillion with nearly 1/3 spent on hospitalizations. Informed by real-world data from an Electronic Health Record (EHR) database of clinical and administrative records spanning 273 million encounters for 60 million patients in 600+ hospitals across the US, Boston Strategic Partners (BSP) Real World data report, Hospital-Treated Pneumonia: Diagnosis, estimates 30% of all hospital discharges involve treatment of infectious organisms. Pneumonia is responsible for an estimated 12% of all hospital stays. At an average cost of $15,500 per occurrence, we estimate that hospitalizations for severe infections account for around $212 billion in annual spending or 7% of total healthcare expenditure. In this report, we conduct an in-depth analysis of pneumonia patient characteristics, costs, and laboratory testing.

Hospital-Treated Pneumonia: Diagnosis

Gram-negative bacteria are the likely causative agents of most pneumonia infections. From 2010-2015, drug resistant organisms caused a surprising 20% of bacterial pneumonia infections. Hospital-Treated Pneumonia: Diagnosis is part one of a two-part series on hospital-treated sepsis. This report provides quantitative, objective data using real-world patient encounters and reflects real physician diagnostic decisions and encounter characteristics (e.g. admissions and lab testing) in key areas, such as antibiotic resistant pathogens.

Table of Contents

1. Patient Flow

2. Executive Summary

3. Incidence and Impact of Disease

  • Incidence
  • Length of Stay
  • Total Cost

4. Patient Demographics

  • Age
  • Insurance type
  • Gender
  • Region
  • Mortality
  • Comorbid Conditions

5. Patient Segmentation by Diagnostic Testing

  • Causative Etiologic Agent

6. Length of Stay and Cost by Patient Segment

  • Age at Admission
  • APACHE II Score
  • First Care Setting

7. Patient Flow through the Hospital

  • Admission Site
  • Lab Testing
  • Lab TAT
  • Results
  • Etiology

8. Drug Resistant Pneumonia

  • Current Trends
  • Costs
  • Comorbidity
  • LOS
  • Mortality

9. Database Overview

10. Methodology